22,436 results match your criteria Salivary Gland Neoplasms


Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Clin Transl Oncol 2022 Jun 23. Epub 2022 Jun 23.

Vall d'Hebron University Hospital, Spanish Society of Pathological Anatomy (SEAP), Barcelona, Spain.

The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein-Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. Read More

View Article and Full-Text PDF

MYB-NFIB fusion transcript in Adenoid Cystic Carcinoma: current state of knowledge and future directions.

Crit Rev Oncol Hematol 2022 Jun 20:103745. Epub 2022 Jun 20.

Academic Unit of Oral and Maxillofacial Medicine and Pathology, Department of Clinical Dentistry, University of Sheffield, Sheffield, UK.

Adenoid cystic carcinoma (ACC) is the most common type of salivary gland cancer that can also arise in other primary sites. Regardless of the site, most ACC cases carry a recurrent chromosomal translocation - t(6;9)(q22-23;p23-24) - involving the MYB oncogene and the NFIB transcription factor. Generally, a long sequence of MYB is fused to the terminal exons of NFIB, yet the break can occur in different exons for both genes, resulting in multiple chimeric variants. Read More

View Article and Full-Text PDF

Application of the Milan System for Reporting Salivary Gland Cytopathology: A Single Institutional Experience of 354 Cases with Cytologic-Histologic Correlation.

Acta Cytol 2022 Jun 23:1-8. Epub 2022 Jun 23.

Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Background: Evaluation of salivary gland lesions is routinely done preoperatively by fine-needle aspiration cytology (FNAC). The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC), with diagnostic categories I-VI, has been recommended to standardize the reporting of salivary gland lesions by FNAC. We aimed to reclassify archival salivary gland FNAC samples using MSRSGC, correlate the samples with surgical resections, and calculate the risk of malignancy (ROM) for each category. Read More

View Article and Full-Text PDF

MALDI Mass Spectrometry Imaging Highlights Specific Metabolome and Lipidome Profiles in Salivary Gland Tumor Tissues.

Metabolites 2022 Jun 8;12(6). Epub 2022 Jun 8.

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.

Salivary gland tumors are relatively uncommon neoplasms that represent less than 5% of head and neck tumors, and about 90% are in the parotid gland. The wide variety of histologies and tumor characteristics makes diagnosis and treatment challenging. In the present study, Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used to discriminate the pathological regions of patient-derived biopsies of parotid neoplasms by metabolomic and lipidomic profiles. Read More

View Article and Full-Text PDF

Heterogeneity of Genetic Landscapes in Salivary Gland Tumors and Their Critical Roles in Current Management.

Medeni Med J 2022 Jun;37(2):194-202

Department of Otorhinolaryngology-Head & Neck Surgery, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan, Malaysia.

Salivary gland neoplasms (SGNs) are rare and heterogeneous tumors in the head and neck region. Although progress has been recently made in revealing the molecular landscape of salivary glands tumors, it is limited and appears to be the tip of the iceberg. Some genetic aberrations include chromosomal translocations, such as CRTC1/3-MAML2 in mucoepidermoid carcinoma, g MYB-NFIB gene fusions in adenoid cystic carcinoma, and PLAG1-HMGA2 gene changes in pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Read More

View Article and Full-Text PDF

Sebaceous carcinoma of the lip: a case report and review of the literature.

J Med Case Rep 2022 Jun 18;16(1):241. Epub 2022 Jun 18.

Department of Clinical and Experimental Medicine, University of Foggia, Via Carelli 28, 71100, Foggia, Italy.

Background: Sebaceous carcinoma is a very rare, aggressive, malignant tumor arising in the adnexal epithelium of the sebaceous gland. Sebaceous carcinoma in the oral cavity is extremely rare, with only 14 cases reported in literature. We reported the fourth case of sebaceous carcinoma involving the lip CASE PRESENTATION: A 71-year-old Caucasian male smoker presented an ulcerated lesion in the lateral region of the lower lip. Read More

View Article and Full-Text PDF

Therapeutic bronchoscopy followed by sequential radiochemotherapy in the management of life-threatening tracheal adenoid cystic carcinoma: a case report.

J Med Case Rep 2022 Jun 20;16(1):243. Epub 2022 Jun 20.

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia.

Background: Adenoid cystic carcinoma of the lung is a distinctive salivary-gland-type malignant epithelial neoplasm that rarely presents as a primary tumor of the respiratory tract. Complete surgical resection remains the treatment of choice for adenoid cystic carcinoma. We present a case of large ACC tumors that caused severe central airway obstruction and were effectively treated with therapeutic bronchoscopy followed by radiotherapy and chemotherapy. Read More

View Article and Full-Text PDF

Head and Neck Cystic Lesions: A Cytology Review of Common and Uncommon Entities.

Acta Cytol 2022 Jun 17:1-12. Epub 2022 Jun 17.

Department of Pathology, The Johns Hopkins University School of Medicine and The Johns Hopkins Hospital, Baltimore, Maryland, USA.

Background: Cystic lesions of the head and neck are a diagnostic challenge since they are seen in the clinical presentation of a wide variety of conditions. Herein, common and uncommon entities that present as cystic lesions in the head and neck are reviewed.

Summary: In this study, peer-reviewed articles were selected using the database PubMed, Google, Google Scholar, and Scopus. Read More

View Article and Full-Text PDF

Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.

Target Oncol 2022 May 18;17(3):321-328. Epub 2022 Jun 18.

Bayer Pharmaceuticals LLC, Whippany, NJ, USA.

Background:  Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers with an estimated prevalence of less than 1% across all solid tumors. Tropomyosin receptor kinase inhibitors (TRKis) block the constitutively activated tyrosine receptor kinase (TRK) fusion protein produced in NTRK gene fusion positive (NTRK+) tumors from downstream signaling. Tropomyosin receptor kinase inhibitors are now first-line (1L) or subsequent treatment options for TRK fusion cancers. Read More

View Article and Full-Text PDF

Mammary analogue secretory carcinoma of parotid gland: Literature review and experience of a dedicated cancer institution in Pakistan.

J Pak Med Assoc 2022 May;72(5):950-953

Department of Surgical Oncology, Lahore,Pakistan.

Mammary Analogue Secretory Carcinoma (MASC) is a rare pathology of the salivary gland, most commonly involving the parotid gland. The objective of this study was to identify the characteristic features of MASC and its treatment outcomes. A retrospective review of 12 patients with histological diagnosis of MASC, who were managed between 2010 to 2019, was carried out at the Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore. Read More

View Article and Full-Text PDF

Microsecretory Adenocarcinoma of the External Ear Canal.

J Cutan Pathol 2022 Jun 16. Epub 2022 Jun 16.

University of Virginia Medical Center, Department of Pathology, P.O. Box 800214, 1215 Lee St, Charlottesville, VA.

Microsecretory adenocarcinoma (MSA) is a recently described salivary gland tumor characterized by unique histomorphologic and immunohistochemical features as well as recurrent MEF2C::SS18 gene fusion. Since 2019, 24 cases have been reported in the literature, primarily arising in the oral cavity, with a single reported case arising in the parotid gland. Here, we present a case of MSA that arose in the external ear canal in an 89-year-old woman and was discovered during management of vertigo symptoms. Read More

View Article and Full-Text PDF

Sebaceous Adenocarcinoma in Parotid Gland of a 65-Year-Old.

S D Med 2022 Apr;75(4):158-160

University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.

Sebaceous adenocarcinoma of the parotid gland is a rare, malignant epithelial neoplasm with focal areas of sebaceous differentiation. A literature search revealed only 34 cases as of December 2020. Our case brings this total to 35. Read More

View Article and Full-Text PDF

Management of Adenoid Cystic Carcinoma of the Head and Neck: Experience of the National Cancer Institute, Egypt.

Gulf J Oncolog 2022 May;1(39):63-69

Department of Surgical Oncology, National Cancer Institute, Cairo University, Egypt.

Purpose: This study presents the experience of the National Cancer Institute, Cairo University, in diagnosis and management of ACC of the head and neck.

Methods: This is a retrospective review of 57 patients with ACC managed during the period from January 2011 to January 2016. Data about the characteristics and management of the disease were recorded. Read More

View Article and Full-Text PDF

Beyond Surgical Treatment in Adenoid Cystic Carcinoma of the Head and Neck: A Literature Review.

Cancer Manag Res 2022 4;14:1879-1890. Epub 2022 Jun 4.

Department of Otorhinolaryngology-Head and Neck Surgery, Sorbonne University, Tenon Hospital, AP-HP, Paris, France.

Introduction: Adenoid cystic carcinoma (AdCC) is a rare tumour as it accounts for about 10% of all salivary gland neoplasms. It occurs in all age groups with a predominance of women, but no risk factors have been identified to date. Although AdCC behaves as a slow-growing tumour, it is characterized by multiple and late recurrences. Read More

View Article and Full-Text PDF

[Radiation therapy of malignant salivary gland tumors].

HNO 2022 Jun 10. Epub 2022 Jun 10.

Universitätsklinikum Heidelberg (UKHD) und Deutsches Krebsforschungszentrum (DKFZ), Nationales Centrum für Tumorerkrankungen (NCT), Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.

Due to their rarity, histologic heterogeneity, and localization, treatment of malignant salivary gland tumors requires an interdisciplinary approach. First-line treatment includes complete tumor resection. Postoperative radiation therapy is advised in patients with risk factors, i. Read More

View Article and Full-Text PDF

Global DNA Methylation Profiling Reveals Differentially Methylated CpGs between Salivary Gland Pleomorphic Adenomas with Distinct Clinical Course.

Int J Mol Sci 2022 May 25;23(11). Epub 2022 May 25.

Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland.

Pleomorphic adenomas (PAs) are the most frequently diagnosed benign salivary gland tumors. Although the majority of PAs are characterized by slow growth, some develop very fast and are more prone to recur. The reason for such differences remains unidentified. Read More

View Article and Full-Text PDF

[Clinicopathological features of clear cell carcinoma of salivary gland in the head and neck].

Zhonghua Bing Li Xue Za Zhi 2022 Jun;51(6):494-499

Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

To investigate the clinical, histologic, immunohistochemical (IHC) and molecular genetic features of clear cell carcinoma (CCC) of salivary gland in the head and neck regions. Seven cases of CCC diagnosed in the Department of Pathology, the First Affiliated Hospital of Nanjing Medical University from 2018 to 2021 were included. The clinical and pathologic data, HE sections and IHC staining were reviewed, and EWSR1 gene translocation was detected by fluorescence in situ hybridization (FISH). Read More

View Article and Full-Text PDF

Salivary gland organoid culture maintains distinct glandular properties of murine and human major salivary glands.

Nat Commun 2022 Jun 7;13(1):3291. Epub 2022 Jun 7.

Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, South Korea.

Salivary glands that produce and secrete saliva, which is essential for lubrication, digestion, immunity, and oral homeostasis, consist of diverse cells. The long-term maintenance of diverse salivary gland cells in organoids remains problematic. Here, we establish long-term murine and human salivary gland organoid cultures. Read More

View Article and Full-Text PDF

Epithelial-myoepithelial carcinoma of the maxillofacial and sinonasal region: a systematic review of presenting characteristics, treatment modalities, and associated outcomes.

Int J Oral Maxillofac Surg 2022 Jun 3. Epub 2022 Jun 3.

Department of Oral and Maxillofacial Surgery, Royal Melbourne Hospital, Victoria, Australia; Department of Oral and Maxillofacial Surgery, Townsville University Hospital, Queensland, Australia.

Epithelial-myoepithelial carcinoma (EMC) is a rare salivary gland malignancy. Controversy exists in the literature regarding the effectiveness of treatment modalities employed in the management of EMC. This systematic review was undertaken to understand the presenting characteristics of EMC and identify the most common treatment modalities and their associated outcomes, in order to help guide an evidenced-based approach to the algorithm of care. Read More

View Article and Full-Text PDF

The association of frailty and outcomes of geriatric assessment with acute radiation-induced toxicity in patients with head and neck cancer.

Oral Oncol 2022 Jul 2;130:105933. Epub 2022 Jun 2.

University of Groningen, Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Background And Purpose: Geriatric impairments and frailty are highly prevalent in patients with head and neck cancer (HNC). This study investigated the association of frailty and outcomes of geriatric assessment (GA) with radiation-induced toxicity (RIT) in patients undergoing (chemo)radiotherapy ((C)RT) for HNC.

Materials And Methods: Between October 2014 and April 2016, patients with HNC were prospectively included in OncoLifeS, an institutional data-biobank. Read More

View Article and Full-Text PDF

The role of perineural invasion in parotid malignancy outcomes: A systematic review and meta-analysis.

Oral Oncol 2022 Jul 1;130:105937. Epub 2022 Jun 1.

Loyola University Medical Center, Department of Otolaryngology, Maywood, IL, USA.

Purpose: At present, perineural invasion is used as a histologic indicator of aggressive salivary gland disease. In other head and neck malignancies, perineural invasion impacts staging of cancer lesions and therefore affects treatment options.

Objective: To compare survival outcomes in primary parotid malignancies with and without perineural invasion. Read More

View Article and Full-Text PDF

Current opinions on diagnosis and treatment of adenoid cystic carcinoma.

Oral Oncol 2022 Jul 2;130:105945. Epub 2022 Jun 2.

Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, Hunan 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; Anatomy Laboratory of Division of Nose and Cranial Base, Clinical Anatomy Center of Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Electronic address:

Adenoid cystic carcinoma (ACC) is a rare malignant tumor derived mainly from the salivary glands, representing approximately 1% of all headandneck carcinomasand 10% of all salivary gland neoplasms. ACC displays a paradoxical behavioral combination of an indolent growth pattern but an aggressive progression, with local recurrence and distant metastasis. The propensity of ACC of the head and neck (ACCHN) for perineural invasion and its anatomical location, especially if it extends to the nasal cavity and paranasal sinuses, facilitates tumor involvement in the surrounding structures, such as the orbit, pterygopalatine fossa, Meckel'scave, and cavernous sinus, which can lead to skull base involvement and intracranial extension. Read More

View Article and Full-Text PDF

Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia.

Acta Oncol 2022 Jul 3;61(7):856-863. Epub 2022 Jun 3.

OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany.

Purpose: We tested the hypothesis that gene expressions from biopsies of locally advanced head and neck squamous cell carcinoma (HNSCC) patients can supplement dose-volume parameters to predict dysphagia and xerostomia following primary radiochemotherapy (RCTx).

Material And Methods: A panel of 178 genes previously related to radiochemosensitivity of HNSCC was considered for nanoString analysis based on tumour biopsies of 90 patients with locally advanced HNSCC treated by primary RCTx. Dose-volume parameters were extracted from the parotid, submandibular glands, oral cavity, larynx, buccal mucosa, and lips. Read More

View Article and Full-Text PDF

Comparing Antegrade and Retrograde Parotidectomy: Surgical Parameters and Complications.

Iran J Otorhinolaryngol 2022 Mar;34(121):83-88

Nuclear Medicine Physician, Mashhad University of Medical Sciences, Mashhad, Iran.

Introduction: Patotidectomy is the treatment of choice for superficial parotid gland lesions. The present study aimed to assess the facial nerve status, as well as peri-and postsurgical complications, in two surgical techniques (antegrade and retrograde) for parotidectomy.

Materials And Methods: This study was conducted on 56 patients diagnosed with parotid neoplasms from 2013-2015. Read More

View Article and Full-Text PDF

Recurrent Parotid Adenocarcinoma Presenting as Diffuse Myocardial Metastatic Disease.

Tex Heart Inst J 2022 05;49(3)

Division of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.

A 64-year-old man who had undergone treatment for left parotid adenocarcinoma presented with progressive exertional shortness of breath. Evaluation revealed metastatic invasion of the myocardium as a rare presentation of recurrent parotid adenocarcinoma. This case highlights the importance of using multimodal imaging methods in diagnostic evaluation and a collaborative multidisciplinary approach in managing patient care. Read More

View Article and Full-Text PDF

Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis.

BMJ Case Rep 2022 May 31;15(5). Epub 2022 May 31.

Surgical Oncology, Kolhapur Cancer Centre, Kolhapur, Maharashtra, India.

Malignant neoplasms of salivary gland neoplasms are rare and often involve the parotid gland. The primary treatment of these malignancies is surgery with or without adjuvant therapy. Chemotherapy or systemic therapy is indicated in recurrent or metastatic disease where surgery or radiotherapy is not possible. Read More

View Article and Full-Text PDF

Detecting patients with Cushing's syndrome: The importance of initial test selection.

Aust J Gen Pract 2022 06;51(6):453-454

BPharm, MBBS (Hons), MAACB, FRCPA, Consultant Pathologist, Department of Biochemistry, Western Diagnostic Pathology, WA; Medical School, The University of Western Australia, Perth, WA.

Background And Objectives: The recommended initial tests for suspected Cushing's syndrome are late-night salivary cortisol (LNSC), 24-hour urinary free cortisol (UFC) and the 1 mg overnight dexamethasone suppression test (ONDST). These tests have higher sensitivity and specificity than serum cortisol. The aim of this study was to determine the relative frequency of these requested tests in primary care. Read More

View Article and Full-Text PDF

Increased MIB-1 expression in salivary gland pleomorphic adenoma that recurs and undergoes malignant transformation.

Sci Rep 2022 May 30;12(1):9029. Epub 2022 May 30.

Department of Pathology, HUSLAB, Helsinki University Hospital and University of Helsinki, PO Box 21, 00014, Helsinki, Finland.

The objective of this retrospective study was to explore possible changes in histopathological features and expression of cyclin D1 and MIB-1 in salivary gland pleomorphic adenoma (PA) that recur or undergo malignant transformation. Knowledge of these characteristics might help to guide the management of these rare tumors. The histopathology and immunohistochemical staining characteristics of such tumors were analyzed in a cohort of 65 patients constituting three different groups of tumors: PA, recurrent pleomorphic adenoma (RPA) and carcinoma ex PA (CxPA). Read More

View Article and Full-Text PDF

Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study.

Oral Oncol 2022 Jul 27;130:105932. Epub 2022 May 27.

Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. Electronic address:

Objectives: In CheckMate 141, nivolumab significantly improved overall survival (OS) in patients with platinum-refractory recurrent or metastatic squamous cell carcinomas (R/M SCC) of the head and neck. However, reports on nivolumab for patients with non-SCC and/or a primary subsite excluded from CheckMate 141 are limited.

Materials And Methods: We conducted a retrospective analysis of R/M head and neck cancer patients who received nivolumab. Read More

View Article and Full-Text PDF

A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.

Target Oncol 2022 May 30;17(3):271-281. Epub 2022 May 30.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, 610 University Avenue, Toronto, M5G 2M9, Canada.

Background: Epidermal growth factor receptor (EGFR)- and human epidermal growth factor receptor (HER)2-targeted therapies are approved for the treatment of breast, gastric/gastrointestinal junction (GEJ), and non-small cell lung cancer (NSCLC) with specific molecular aberrations affecting HER family members. Over 10 % of other cancers harbor genomic aberrations affecting HER family members, but their role remains undefined.

Objective: The MOBILITY3 trial evaluated the antitumor activity of afatinib, an oral pan-HER tyrosine kinase inhibitor (TKI) in HER-aberrant tumors outside of the licensed indications. Read More

View Article and Full-Text PDF